Surgical-pathologic factors affect long-term outcomes in stage IB (pT2 N0 M0) non-small cell lung cancer: a heterogeneous disease
- PMID: 19619791
- DOI: 10.1016/j.jtcvs.2008.12.035
Surgical-pathologic factors affect long-term outcomes in stage IB (pT2 N0 M0) non-small cell lung cancer: a heterogeneous disease
Abstract
Objectives: Our objective was to identify surgical-pathologic factors affecting prognosis in stage IB non-small cell lung cancers.
Methods: Between 1997 and 2006, a cohort of 272 cases of pT2 N0 M0 stage lung cancer were retrospectively analyzed. The patients included 70 women and 202 men with a mean age of 67.0 years. The surgical resections included pneumonectomy in 4, bilobectomy or lobectomy in 217, and limited resections in another 51. The impact of surgical-pathologic characteristics on survival, including cell type, tumor differentiation, tumor size, depth of visceral pleural invasion, type of surgical resection, and extent of lymphadenectomy on patient survival, was compared accordingly.
Results: Tumor types included adenocarcinoma/bronchioloalveolar carcinoma in 142, squamous cell carcinoma in 100, and others in 30. Cell differentiations were classified as well, moderately, and poorly differentiated in 23, 151, and 92 cases, respectively. The mean tumor size was 3.9 cm in diameter, and the average resected lymph node number was 14.3. Direct visceral pleural or subpleural invasions (<1 mm) were found in 134 and 42 cases, respectively. Angiolymphatic invasions were seen in 26 cases, and positive tumor margins were found in 14 cases. The overall 5-year and 10-year survivals were 59.5% and 41.3%, respectively. Good prognostic factors using univariate analysis included female gender, nonlimited resection, well-differentiated tumor, no angiolymphatic invasion, smaller size (<or=3 cm), and numbers of nodes retrieved (>14 nodes). However, the Cox proportional hazard model revealed female gender, well-differentiated tumor, no pleural involvement, no angiolymphatic invasion, and more than 14 nodes retrieved as independent good prognostic factors.
Conclusions: Stage IB lung cancer can be treated by standard pulmonary resection accompanied by adequate mediastinal lymphadenectomy. Owing to the heterogeneity of stage IB lung cancer and the fact that prognosis can be affected by many surgical-pathologic factors, refinement of the current TNM staging criteria may be needed.
Similar articles
-
Prognostic factors in resected stage I non-small cell lung cancer with a diameter of 3 cm or less: visceral pleural invasion did not influence overall and disease-free survival.J Thorac Cardiovasc Surg. 2007 Sep;134(3):638-43. doi: 10.1016/j.jtcvs.2007.04.059. J Thorac Cardiovasc Surg. 2007. PMID: 17723811
-
Completely resected N1 non-small cell lung cancer: factors affecting recurrence and long-term survival.J Thorac Cardiovasc Surg. 2006 Sep;132(3):499-506. doi: 10.1016/j.jtcvs.2006.04.019. Epub 2006 Jul 28. J Thorac Cardiovasc Surg. 2006. PMID: 16935101
-
Subcategorization of lung cancer based on tumor size and degree of visceral pleural invasion.Ann Thorac Surg. 2008 Oct;86(4):1084-90. doi: 10.1016/j.athoracsur.2008.04.117. Ann Thorac Surg. 2008. PMID: 18805136
-
The present status of surgery for lung cancer.Acta Chir Belg. 1996 Nov-Dec;96(6):245-51. Acta Chir Belg. 1996. PMID: 9008764 Review.
-
Arterial invasion predicts early mortality in stage I non-small cell lung cancer.Ann Thorac Surg. 2004 Nov;78(5):1748-53. doi: 10.1016/j.athoracsur.2004.04.061. Ann Thorac Surg. 2004. PMID: 15511466 Review.
Cited by
-
The Role of Race and Economic Characteristics in the Presentation and Survival of Patients With Surgically Resected Non-Small Cell Lung Cancer.Front Oncol. 2018 May 14;8:146. doi: 10.3389/fonc.2018.00146. eCollection 2018. Front Oncol. 2018. PMID: 29868470 Free PMC article.
-
Surgical outcomes of pulmonary mucoepidermoid carcinoma: A review of 41 cases.PLoS One. 2017 May 2;12(5):e0176918. doi: 10.1371/journal.pone.0176918. eCollection 2017. PLoS One. 2017. PMID: 28463970 Free PMC article.
-
Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.Future Oncol. 2021 Dec;17(34):4785-4795. doi: 10.2217/fon-2021-0517. Epub 2021 Aug 26. Future Oncol. 2021. PMID: 34435876 Free PMC article.
-
Integrating Pathologic Stage and Perioperative Circulating Tumor Cell Variations: Early Relapse Prediction Model for Resectable Non-Small Cell Lung Cancer.JCO Precis Oncol. 2025 Apr;9:e2400709. doi: 10.1200/PO-24-00709. Epub 2025 Apr 28. JCO Precis Oncol. 2025. PMID: 40294350 Free PMC article.
-
Lymph but Not Blood Vessel Invasion Is Independent Prognostic in Lung Cancer Patients Treated by VATS-Lobectomy and Might Represent a Future Upstaging Factor for Early Stages.Cancers (Basel). 2022 Apr 8;14(8):1893. doi: 10.3390/cancers14081893. Cancers (Basel). 2022. PMID: 35454799 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical